论文部分内容阅读
1商品名Naglazyme2开发与上市厂商本品由BioMarin公司研发,于2005年6月在美国首次上市。3适应证本品适用于Ⅵ型黏多糖增多症患者,可改善患者的行走和爬楼梯能力。4药理作用Ⅵ型黏多糖增多症是由于N-乙酰半乳糖胺-4-硫酸酯酶的缺乏或明显减少引起的。这种硫酸酯酶活性缺乏导致其
1 Name Naglazyme2 Development and listing of manufacturers This product was developed by BioMarin company, in June 2005 for the first time in the United States. 3 indications This product is suitable for type â ... ¡Mucopolysaccharidosis patients, patients can improve walking and climbing ability. 4 pharmacological effects Ⅵ type mucopolysaccharidosis is due to the lack of N-acetylgalactosamine-4-sulfatase or significantly reduced cause. This lack of sulfatase activity leads to it